Hemochromatosis Management and Pathophysiology

Introduction to Hemochromatosis

Hemochromatosis is a genetic disorder characterized by excessive iron absorption that leads to progressive iron accumulation in organs, causing significant morbidity and mortality if left untreated, but early diagnosis and treatment with phlebotomy can normalize life expectancy, as recommended by the American Association for the Study of Liver Diseases 1, 2

Hereditary hemochromatosis (HH) is predominantly caused by mutations in the HFE gene located on chromosome 6p, with C282Y homozygosity (C282Y/C282Y) found in >90% of patients with phenotypic HH, according to the American College of Gastroenterology 3, 4
The prevalence of C282Y homozygosity is approximately 1 in 250 individuals of European descent, particularly those of Nordic or Celtic ancestry, as stated by the European Association for the Study of the Liver 4, 1
Despite the high prevalence of genetic susceptibility, fewer than 10% of C282Y homozygotes develop full clinical manifestations of the disease, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 1, 2

The classic triad of "bronze diabetes": cirrhosis, diabetes, and skin pigmentation, is a common presentation of hemochromatosis, as described by the American Diabetes Association 1
Common symptoms include fatigue and weakness (19-83% of patients), arthralgias (13-57%), abdominal pain (0-58%), sexual dysfunction (12-56%), and cardiac failure symptoms (0-35%), according to the American Heart Association 1
Physical findings include hepatomegaly (3-83%), skin pigmentation (5-82%), cirrhosis (3-94%), clinical diabetes (6-55%), and testicular atrophy (14-50%), as documented by the Endocrine Society 1

Liver: Fibrosis, cirrhosis, hepatocellular carcinoma, are common complications of hemochromatosis, as reported by the American Association for the Study of Liver Diseases 3, 1
Pancreas: Diabetes mellitus, is a frequent complication of hemochromatosis, according to the American Diabetes Association 1
Heart: Cardiomyopathy, congestive heart failure, are potential complications of hemochromatosis, as stated by the American Heart Association 1

Screening should target first-degree relatives of confirmed HH cases, patients with unexplained liver disease or abnormal iron studies, individuals with type 2 diabetes, particularly with hepatomegaly or elevated liver enzymes, and patients with early-onset atypical arthropathy, cardiac disease, or male sexual dysfunction, as recommended by the American College of Gastroenterology 5
Initial testing includes transferrin saturation (TS) and serum ferritin, which reflects hepatic iron content, according to the National Institute of Diabetes and Digestive and Kidney Diseases 3, 5

Early diagnosis to prevent organ damage, screening and early detection of asymptomatic cases to reduce mortality, adequate treatment to promote rapid, safe, and effective removal of iron, and vigilant follow-up and maintenance treatment, are the primary goals of hemochromatosis management, as stated by the American Association for the Study of Liver Diseases 3
Phlebotomy is the primary therapy for iron depletion, and treatment should be initiated before development of cirrhosis or diabetes to normalize survival, according to the American College of Gastroenterology 3

The degree of iron overload directly impacts life expectancy, and major causes of death include decompensated cirrhosis, hepatocellular carcinoma, diabetes mellitus, and cardiomyopathy, as reported by the National Institute of Diabetes and Digestive and Kidney Diseases 3
Survival is normal in patients treated before development of cirrhosis or diabetes, as stated by the American Association for the Study of Liver Diseases 3